Inhibrx Biosciences, Inc. (INBX) delivered a return of 544.58% over the past year. Since INBX does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Inhibrx Biosciences, Inc. one year ago would be worth $64,458 today, representing a gain of $54,458.

Inhibrx Biosciences, Inc. (INBX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For INBX, the total return equals the price-only return.

Yes, Inhibrx Biosciences, Inc. (INBX) outperformed the S&P 500 by 523.74 percentage points over the past year. INBX delivered a total return of 544.58%, compared to the S&P 500's 20.84%. This 523.74pp alpha means investors in INBX earned more than a passive S&P 500 index fund.

Inhibrx Biosciences, Inc. (INBX) experienced a maximum drawdown of -38.66% over the past year, declining from its peak on 2026-05-06 to its trough on 2026-06-05. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Inhibrx Biosciences, Inc. (INBX)'s long-term returns with dividends reinvested. Over 10 years, the total return is 365.3% (16.6% CAGR) — $10,000 would have grown to $46,529. Over 20 years: 365.3% total return (8.0% CAGR) — $10,000 → $46,530. Over 30 years: 365.3% total return (5.3% CAGR) — $10,000 → $46,529. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Inhibrx Biosciences, Inc.'s best calendar year was 2025 with a total return of 418.0%. Its worst year was 2024 with a total return of -57.3%. This range shows the volatility investors should expect — the difference between the best and worst year is 475.3 percentage points.